A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Tarapeutics Science Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05241093
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
- Conditions
- MyelodysplasiaAcute Myeloid Leukemia
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Magenta Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05223699
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesLeukemia, Myeloid, Acute
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 290
- Registration Number
- NCT05218902
- Locations
- 🇨🇳
Local Institution - 0001, Tianjin, Tianjin, China
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT05215639
- Locations
- 🇦🇹
Klinikum Klagenfurt am Wörthersee /ID# 247304, Klagenfurt am Wörthersee, Kaernten, Austria
🇨🇭Duplicate_Universitätsspital Basel /ID# 256509, Basel, Basel-Stadt, Switzerland
🇨🇭Inselspital, Universitaetsspital Bern /ID# 239241, Bern, Switzerland
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 19
- Registration Number
- NCT05197426
- Locations
- 🇺🇸
Local Institution - 0011, Huntsville, Alabama, United States
🇯🇵Local Institution - 0017, Nagoya, Aichi-ken, Japan
🇯🇵Local Institution - 0023, Nagoya, Aichi-ken, Japan
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
- Conditions
- FLT3-TKD MutationFLT3-ITDRefractory AMLRelapsed Adult AML
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 177
- Registration Number
- NCT05193448
- Locations
- 🇫🇷
Amiens CHU, Amiens, France
🇫🇷Angers CHU, Angers, France
🇫🇷Avignon CH, Avignon, France
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
- Interventions
- Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05190471
- Locations
- 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States
Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: Best Supportive Care
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Associazione Qol-one
- Target Recruit Count
- 54
- Registration Number
- NCT05188326
- Locations
- 🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
🇮🇹Ospedale Riuniti, Ancona, AN, Italy
🇮🇹A.O. S. Giovanni Moscati, Avellino, AV, Italy
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 16
- Registration Number
- NCT05188170
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 98
- Registration Number
- NCT05183035
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States